Bio CDMO space welcomes this new but established player
Celltrion (KRX:068270) launched its Bio CDMO (Contract Development and Manufacturing) business, on a quest to pursue open innovation for development of new drugs.
Company’s focus activities under this BU include but are not limited to:
- Outsourcing of biologic cell line development and production process, etc.,
- Manufacture outsourcing of non-clinical material, clinical material, and commercialised material.
Taking in-development products to pool of commercialisation is claimed to be major objective of this CDMO venture.
Celltrion plans to support end client through accumulated expertise in bio-pharma space, and may explore strategic alliance or in-licensing deal with its end clientele.
Biologics, Biosimilar, Biotechnology, and CMO